Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
The combination of Ftorafur (NSC-148958) and methyl-CCNU (NSC-95441) was evaluated in 36 patients with advanced colorectal cancer. The principle toxicities encountered were myelosuppression, gastrointestinal, and neurological. There were no complete responses and only 5/34 (14.7%) patients achieved a partial response. Methyl-CCNU and Ftorafur does not appear to be an effective combination in advanced adenocarcinoma of the colon and rectum.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008875:Middle Aged; D009420:Nervous System / Q000187:drug effects; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012673:Semustine / Q000008:administration & dosage* / Q000009:adverse effects / Q000633:toxicity; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects
D009607:Nitrosourea Compounds; D012673:Semustine; D005641:Tegafur; D005472:Fluorouracil